PUMA BIOTECHNOLOGY, INC.
Data quality: 100%
PBYI
Nasdaq
Manufacturing
Chemicals
$7.78
▼
$0.02
(-0.26%)
Mkt Cap: 392.26 M
Price
$7.71
Mkt Cap
392.26 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—
Quick Summary
Key Takeaways
Revenue declined -2.54% annually over 5 years
ROE of 28.28% indicates high profitability
Debt/Equity of 0.30 — conservative balance sheet
Generating 41.73 M in free cash flow
P/E of 12.61 — trading at a low valuation
Cash machine — converts 134.14% of earnings into free cash flow
Growth
Revenue Growth (5Y)
-2.54%
Below sector avg (1.82%)
Revenue (1Y)-0.91%
Earnings (1Y)2.75%
FCF Growth (3Y)24.62%
Quality
Return on Equity
28.28%
Above sector avg (-53.34%)
ROIC27.49%
Net Margin13.62%
Op. Margin16.33%
Safety
Debt / Equity
0.30
Below sector avg (0.31)
Current Ratio1.74
Interest Coverage5.63
Valuation
PE (TTM|2027)
12.61 | 11.86
Above sector avg (-1.47)
P/B Ratio3.40
EV/EBITDA7.73
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 12.6 | -1.5 |
| P/B | 3.4 | 1.6 |
| ROE % | 28.3 | -53.3 |
| Net Margin % | 13.6 | -41.5 |
| Rev Growth 5Y % | -2.5 | 1.8 |
| D/E | 0.3 | 0.3 |
Analyst Price Target
1 analyst
Hold
Current
$7.78
Target
$5.00
$5.00
$5.00
$5.00
Forecast
Forward P/E
11.97
Forward EPS
$0.65
EPS Growth (est.)
+62.5%
Est. Revenue
218.00 M
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2027 |
$0.65
$0.65 – $0.65
|
218.00 M | 1 |
| FY2026 |
$0.40
$0.40 – $0.40
|
218.00 M | 1 |
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| 2026 Q2 |
$0.07
$0.07 – $0.07
|
52.00 M | 1 |
| 2026 Q1 |
-$0.13
-$0.13 – -$0.13
|
42.00 M | 1 |
Earnings Surprises
Last 4 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| Q42025 | $0.23 | $0.29 | +26.1% |
| Q32025 | $0.09 | $0.21 | +133.3% |
| Q22025 | $0.07 | $0.15 | +114.3% |
| Q12025 | $0.03 | $0.10 | +300.0% |
ETFs Holding This Stock
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -0.91% | Revenue Growth (3Y) | -1.55% |
| Earnings Growth (1Y) | 2.75% | Earnings Growth (3Y) | 20.04% |
| Revenue Growth (5Y) | -2.54% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 228.37 M | Net Income (TTM) | 31.11 M |
| ROE | 28.28% | ROA | 15.64% |
| Gross Margin | N/A | Operating Margin | 16.33% |
| Net Margin | 13.62% | Free Cash Flow (TTM) | 41.73 M |
| ROIC | 27.49% | FCF Growth (3Y) | 24.62% |
| Safety | |||
| Debt / Equity | 0.30 | Current Ratio | 1.74 |
| Interest Coverage | 5.63 | Asset Turnover | 1.15 |
| Working Capital | 60.85 M | Tangible Book Value | 115.27 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 12.61 | Forward P/E | N/A |
| P/B Ratio | 3.40 | P/S Ratio | 1.72 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 7.73 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 10.64% | ||
| Market Cap | 392.26 M | Enterprise Value | 372.74 M |
| Per Share | |||
| EPS (Diluted TTM) | 0.61 | Revenue / Share | 4.49 |
| FCF / Share | 0.82 | OCF / Share | 0.82 |
| EPS CAGR (1Y) | -1.61% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0.03% | FCF Conversion | 134.14% |
| SBC-Adj. FCF | 34.03 M | Growth Momentum | 1.63 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 228.37 M | 230.47 M | 235.64 M | 228.03 M | 253.16 M |
| Net Income | 31.11 M | 30.28 M | 21.59 M | 2,000.0 | -29.13 M |
| EPS (Diluted) | 0.61 | 0.62 | 0.45 | 0.00 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | 37.30 M | 30.97 M | 32.64 M | 23.72 M | 1.29 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | 71.87 M |
| SG&A Expenses | 70.85 M | 80.16 M | 89.93 M | 89.98 M | 116.29 M |
| D&A | 10.94 M | 11.52 M | 11.52 M | 8.92 M | 10.60 M |
| Interest Expense | 6.62 M | 12.45 M | 13.33 M | 11.59 M | 12.81 M |
| Income Tax | 4.67 M | -6.18 M | 1.08 M | 455,000.0 | 324,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 216.30 M | 213.33 M | 230.53 M | 222.06 M | 226.59 M |
| Total Liabilities | 85.96 M | 121.21 M | 177.09 M | 200.45 M | 229.03 M |
| Shareholders' Equity | 130.34 M | 92.13 M | 53.44 M | 21.61 M | -2.45 M |
| Total Debt | 22.68 M | 68.00 M | 102.00 M | 102.00 M | 102.00 M |
| Cash & Equivalents | 29.64 M | 69.22 M | 84.59 M | 76.20 M | 63.13 M |
| Current Assets | 162.69 M | 147.66 M | 156.19 M | 134.28 M | 140.02 M |
| Current Liabilities | 81.25 M | 96.11 M | 99.38 M | 77.48 M | 109.59 M |
{"event":"ticker_viewed","properties":{"ticker":"PBYI","listing_kind":"stock","pathname":"/stocks/pbyi","exchange":"Nasdaq","country":"US"}}